Abstract
Diabetes mellitus, including type 1 and type 2 diabetes mellitus (2-DM) are the main threats to human health in the worldwide. Protein tyrosine phosphatase 1B (PTP1B) is a promising molecular level legitimate therapeutic target in the effective management of 2-DM. For the search of potent PTP1B inhibitors, much investigation has revealed a large number of small-molecule compounds obtained from natural sources or prepared by synthesis/semi-synthesis with various skeletons and promising anti-PTP1B activities in the treatment of 2-DM. Although some reviews on the development of PTP1B inhibitors have been published, they were mainly concentrated on the results reported in journal articles. In this review, we will provide an overview of the developments of the potent PTP1B inhibitors claimed in recent patents during the past five years (2009-2013) with their structural features and biological features, as well as the structure-activity relationships (SARs) and strategies for finding potent and specific PTP1B inhibitors. This paper will provide valuable information for understanding the current anti-PTP1B investigation and developing potent PTP1B inhibitors as treating 2-DM drugs.
Keywords: Chemical modification, diabetes mellitus, natural products, patents, PTP1B inhibitors, synthesized compounds, type 2 diabetes mellitus (2-DM).
Mini-Reviews in Medicinal Chemistry
Title:Small Molecules as Potent Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors Documented in Patents from 2009 to 2013
Volume: 15 Issue: 2
Author(s): Li-Jun Wang, Bo Jiang, Ning Wu, Shuai-Yu Wang and Da-Yong Shi
Affiliation:
Keywords: Chemical modification, diabetes mellitus, natural products, patents, PTP1B inhibitors, synthesized compounds, type 2 diabetes mellitus (2-DM).
Abstract: Diabetes mellitus, including type 1 and type 2 diabetes mellitus (2-DM) are the main threats to human health in the worldwide. Protein tyrosine phosphatase 1B (PTP1B) is a promising molecular level legitimate therapeutic target in the effective management of 2-DM. For the search of potent PTP1B inhibitors, much investigation has revealed a large number of small-molecule compounds obtained from natural sources or prepared by synthesis/semi-synthesis with various skeletons and promising anti-PTP1B activities in the treatment of 2-DM. Although some reviews on the development of PTP1B inhibitors have been published, they were mainly concentrated on the results reported in journal articles. In this review, we will provide an overview of the developments of the potent PTP1B inhibitors claimed in recent patents during the past five years (2009-2013) with their structural features and biological features, as well as the structure-activity relationships (SARs) and strategies for finding potent and specific PTP1B inhibitors. This paper will provide valuable information for understanding the current anti-PTP1B investigation and developing potent PTP1B inhibitors as treating 2-DM drugs.
Export Options
About this article
Cite this article as:
Wang Li-Jun, Jiang Bo, Wu Ning, Wang Shuai-Yu and Shi Da-Yong, Small Molecules as Potent Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors Documented in Patents from 2009 to 2013, Mini-Reviews in Medicinal Chemistry 2015; 15 (2) . https://dx.doi.org/10.2174/1389557515666150203144339
DOI https://dx.doi.org/10.2174/1389557515666150203144339 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress in Polycystic Ovary Syndrome
Current Pharmaceutical Design NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy
Current Vascular Pharmacology Environmental (Lifestyle) Risk Factors for LADA
Current Diabetes Reviews Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research
Current Alzheimer Research The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling
Current Pharmaceutical Design Propionate: Hypophagic Effects Observed in Animal Models Might be Transposed to the Human Obesity Management
Current Nutrition & Food Science Intracellular Redox Signaling as Therapeutic Target for Novel Antiviral Strategy
Current Pharmaceutical Design Editorial (Thematic Issue: Current Updates on Association Between Alzheimer’s Disease and Type 2 Diabetes Mellitus - Volume II)
CNS & Neurological Disorders - Drug Targets PACAP in the Glucose and Energy Homeostasis: Physiological Role and Therapeutic Potential
Current Pharmaceutical Design Emerging Novel Treatment Strategies for Diabetic Eye Diseases
Current Diabetes Reviews The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade
Current Drug Targets Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry
Current Medicinal Chemistry Meet Our Editorial Board Member:
Applied Clinical Research, Clinical Trials and Regulatory Affairs Therapeutic Nanosystems for Oral Administration of Insulin
Current Pharmaceutical Biotechnology Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued)